1195178-97-2

Upstream product

• 100-58-3 phenylmagnesium bromide 
• 4746-97-8 cyclohexanedione monoethylene ketal 
• 94112-58-0 4-hydroxy-4-phenyl-cyclohexanone ethylene ketal 

Downstream Products

• 79741-43-8 8-phenyl-1,4-dioxaspiro[4.5]decan-8-amine 
• 1195179-05-5 1-(4-(2-methylpyridin-4-yl)phenyl)-3-(4-oxo-1-phenylcyclohexyl)urea 
• 1195173-44-4 1-(4-hydroxy-1-phenylcyclohexyl)-3-(4-(2-methylpyridin-4-yl)phenyl)urea 
• 1195173-47-7 1-(4,4-difluoro-1-phenylcyclohexyl)-3-(4-(2-methylpyridin-4-yl)phenyl)urea 
• 1195179-01-1 1-(4-(2-methylpyridin-4-yl)phenyl)-3-(8-phenyl-1,4-dioxaspiro[4.5]decan-8-yl)urea 

Relevant academic research and scientific papers

UREA COMPOUNDS AS GAMMA SECRETASE MODULATORS

The present invention provides compounds Formula (I) that are gamma secretase modulators and are therefore useful for the treatment of diseases treatable by modulation of gamma secretase such as Alzheimer's disease. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Cyclohexane derivatives and their use as therapeutic agents

The present invention relates compounds of formula (I), wherein ring A is a phenyl or pyridyl ring; X represents a linker selected from the group consisting of formulae: (a), (b), (c), (d), and (e); and R1, R2, R3, R4, R5, R6, R7, R13, R14, R15, R16, R17, R21a and R21b are as defined herein. The compounds are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migraine, emesis or postherpetic neuralgia.